Alira Health

BIO-Europe Autumn 2024

November 4 - 6, 2024 | Stockholm, Sweden

We are pleased to announce that we will attend BIO-Europe Autumn, a premier event spanning the global life science ecosystem to propel dealmaking and innovation.

Take this opportunity to connect with our delegates and discover how we can help you to structure your drug development process into a series of clear and reachable value inflection points to create an innovative product that brings medical value to patients.

Want to meet at Bio Europe? Contact us to set up a meeting. 

Meet Our Delegates

Ben Chambon
Joris Pezzini

Joris Pezzini
Executive Vice President,
Biopharma

Tabatha Bourgois

Tabatha Bourgois
Director, Global Regulatory Business Development

Victoria Blanckenstein

Victoria Blanckenstein
Senior Director,
Clinical Operations

Discover Our Article Series: “Biotech Challenges and Ways to Overcome Them”

In this interview, Joris Pezinni provides an analysis of the current biotech industry, major trends, and the three fundamental functions that executives must address.

Learn more 

Biotech expert Joris Pezzini covers the fundamentals of planning, one of the three required jobs for biotech leaders to be successful.

Learn more

Biotech expert Joris Pezzini and Chris Rao, Senior Vice President of Clinical Operations, discuss one of the most crucial aspects of execution: clinical trials. 

Learn more

Discover Our Biotech Case Studies

A biotech company sought support in the design of their Phase II clinical trial to test the safety and efficacy of a novel inhibitor in combination with Pembrolizumab in patients with Head and Neck Squamous Cell Carcinoma.

Learn more  

A US biopharma needed to validate the patient journeys and US reimbursement pathways for their two alpha-emitting radioligand therapies in two solid tumor indications. They also sought to understand the suitable price points for each asset.

Learn more

A European biotech specializing in the development of radioligand therapies (RLTs) sought to assess the sales potential of its drug candidate, considering the current and future market landscape, especially the positioning of prostate-specific membrane antigen-targeting RLTs.

Learn more 

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.